Venous thromboembolism in women

Vascular Medicine

Volumn 13, Issue 3, 2008, Pages 255-266

  Rathbun, Suman ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Contraception; Hormone replacement therapy; Pregnancy; Venous thrombosis; Women

Indexed keywords

ACETYLSALICYLIC ACID; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; ETYNODIOL DIACETATE; FONDAPARINUX; GESTAGEN; GESTODENE; HEPARIN; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NANDROLONE DERIVATIVE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALOXIFENE; TAMOXIFEN;

ARTICLE; COMPRESSION GARMENT; CONTRACEPTION; DOSE RESPONSE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LOW DRUG DOSE; OSTEOPOROSIS; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; ESTROGEN THERAPY; PREGNANCY COMPLICATION; REVIEW;

CONTRACEPTION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 58149402367     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07085404     Document Type: Article

References (123)

1. Di Minno G, Mannucci P, Tufano A, et al. The first ambulatory screening on thromboembolism: A multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost 2005; 3: 1459-1466.
2. Simon T, De Jonage-Canonico B, Oger E, et al. Indicators of lifetime estrogen endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 2006; 4: 71-76.
3. Grady D, Wenger N, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2000; 132: 689-696.
4. Samama M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius Study. Arch Intern Med 2000; 160: 3415-3420.
5. Kyrle P, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
6. Cushman M, Glynn R, Goldhaber S,et al. Hormonal factors and risk of recurrent venous thrombosis: The Prevention of Recurrent Venous Thromboembolism trial. J Thromb Haemost 2006; 4: 2199-2203.
7. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000; 160: 761-768.
8. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
9. Kyrle P, Eichinger S, Weltermann A. Recurrent venous thromboembolism in men and women [letter]. N Engl J Med 2004; 351:2018.
10. David P, Boatwright E, Tozer B. Hormonal contraception update. Mayo Clin Proc 2006; 81: 949-955.
11. Poulter N, Chang C. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-1582.
12. Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
13. Farmer R, Lawrenson R, Thompson C, Kennedy J, Hambleton I. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
14. Wu O, Roberston L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilia and risk of venous thromboembolism: A systematic review. Thromb Haemost 2005; 94: 17-25.
15. Romero A, Alonso C, Rincon M, et al. Risk of venous thromboembolic disease in women. A qualitative systematic review. Eur J Obstet Gynecol Reprod Biol 2005; 121:8- 17.
16. Hoffman R, Brenner B. Thrombophilia related issues in women and children. Semin Thromb Haemost 2005; 31: 97-103.
17. Van Vlijmen E, Brouwer J, Veeger N, Eskes T, de Graeff P, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch Intern Med 2007; 167: 282-289.
18. De Stefano V, Ross E, Leone G. Inherited thrombophilia, pregnancy and oral contraceptive use: Clinical implications. Semin Vasc Med 2003; 3: 47-59.
19. MacGillavry M, Prins M. Oral contraceptives and inherited thrombophilia: a gene-environment interaction with a risk of venous thrombosis. Semin Thromb Haemost 2003; 29: 219-226.
20. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-326.
21. Tans G, Bouma B, Buller H, Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med 2003; 3: 61-68.
22. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-1600.
23. Vandenbroucke J, Rosing J, Bloemenkamp K, et al. Medical progress: Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
24. Bloemenkamp K, Rosendaal F, Helmerhorst F, Vandenbroucke J. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
25. Gomes M, Deitcher S. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004; 164: 1965-1976.
26. Farley T, Meirik O, Marmot M, Chang C, Poulter N. Oral contraceptives and risk of venous thromboembolism: Impact of duration of use. Contraception 1998; 57: 61-65.
27. Rosendaal F. Thrombosis iA the young: Epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6.
28. Tanis B. vanden Bosch, M, Kemmeren, J, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-1793.
29. Jick H, Kaye J, Vasilakis-Scaramozza C, Jick S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis. BMJ 2000; 321: 1190-1195.
30. Abdollahi M, Cushman M, Rosendaal FR. Obesity: Risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498.
31. Bloemenkamp K, Rosendaal F, Helmerhorst F, Buller H, Vandenbroucke J. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346:1593-1596.
32. Bloemenkamp P, Rosendaal F, Buller H, Helmerhorst F, Colly L, Vandenbroucke J. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65-70.
33. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-1380.
34. Gerstman B, Piper J, Tomita D, Ferguson W, Stadel B, Lundin F. Oral contraceptive estrogen dose and the risk of deep venous thromboembolism disease. Am J Epidemol 1991; 133: 32-37.
35. Lidegard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception 2002; 65: 187-196.
36. Kemmeren J, Algra A, Grobbee D. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ 2001; 323: 131-134.
37. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
38. Anderson F, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006; 73:229-234.
39. Jick S, Kaye J, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 2006; 73: 223-228.
40. Van den Heuvel MW, van Bragt AJ, Alnabawy, AK, Kaptein, MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch, and an oral contraceptive. Contraception 2005; 72: 168-174.
41. Lindqvist PG, Rosing J, Malmquist A, Hillarp A. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 2003; 1: 601-602.
42. Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant. Contraception 1998; 58: 93-98.
43. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-oral contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998; 57:315-324.
44. Vasilakis C, Jick H, Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1611.
45. Vasilakis C, Jick S, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83.
46. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of Factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
47. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P. Interaction between the G20210 mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-703.
48. Spannagl M, Heinemann L, Shramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism. Eur J Contracept Reprod Health Care 2000; 5: 105-112.
49. Rosendaal F, Koster T, Vandenbroucke J, Reitsma P. High risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 85: 1504-1508.
50. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestations of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-490.
51. Mohllajee A, Curtis K, Martins S, Peterson H. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006; 73: 166- 178.
52. Legnani, C, Cini, M, Cosmi, B, Mattarozzi, S, Lo Manto, G, Palaret G. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. Thromb Haemost 2004; 91: 712-718.
53. Andersen B, Olsen J, Nielsen G, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 28-31.
54. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III, protein C, and protein S deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost 1994; 71: 548-552.
55. Bloemenkamp K, Helmerhorst F, Rosendaal F, Vandenbroucke J. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024-1027.
56. Van Hylckama Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J Thromb Haemost 2003; 1: 2186-2190.
57. Martinelli I, Rosendaal F, Vandenbroucke J, Mannucci P. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost 1996; 76: 477-478.
58. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-394.
59. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338: 1793-1797.
60. De Bruijn S, Stam J, Kiipman M, Vandenbroucke J. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589-592.
61. Janssen J, Meinardi J, Vleggaar F et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000; 96:2364-2368.
62. Oral contraceptives, venous thrombosis, and varicose veins. Royal College of General Practitioners' Oral Contraception Study. J R Coll Gen Pract 1978; 28: 393-399.
63. Brandjes D, Buller H, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762.
64. Heit J, Kobbervig C, James A, Petterson T, Bailey K, Melton J. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
65. James A, Jamison M, Brancazio L, Myers E. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315.
66. Berg, C, Atrash H, Koonin L, Tucker M. Pregnancy-related mortality in the United States, 1987-90. Obstet Gynecol 1996; 88: 161-167.
67. Lockwood, C. Pregnancy-associated changes in the hemostatic system. Clin Obstet 2006; 49: 836-843.
68. Stein, P, Hull, R, Kayali F, et al. Venous thromboembolism pregnancy: 21-year trends. Am J Med 2004; 117: 121-125.
69. Lee R. Thromboembolism in pregnancy: A continuing conundrum. Ann Intern Med 2005; 143: 749-750.
70. Jacobsen, A, Drolsum, A, Klow, N, Dahl, G, Qvigstad, E, Sandset, P. Deep vein thrombosis after elective cesarean section. Thromb Res 2004; 113: 283-288.
71. Rodger, M, Avruch, L, Howley, H, Olivier, A, Walker, M. Pelvic magnetic resonance venography reveals high rate of pelvic vein thrombosis after cesarean section. Am J Obstet Gynecol 2006; 194: 436-437.
72. Deneux-Tharaux, C, Carmona, E, Bouvier-Colle, M, Breart G. Postpartum maternal mortality and cesarean delivery. Obstet Gynecol 2006; 108: 541-548.
73. Cole K, Ford I, Greaves M, Watson H. Coagulation activation in women with hyperemesis gravidarum. J Thromb Haemost 2005:3 (Suppl 1).
74. Ergas D, Levin D, Elbirt D, Shelanger H, Sokolovsky N, Sthoeger Z. Internal jugular vein thrombosis following mild ovarian hyperstimulation syndrome in women with Factor V Leiden mutation. Am J Med Sci 2006; 332: 131-133.
75. Nelson S, Greer I. Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery and puerperium. Obstet Gynecol Clin North Am 2006; 33: 413-427.
76. Biron-Andreani C, Schved J, Daures, JP. Factor, V. Leiden mutation and pregnancy-related venous thromboembolism: What is the exact risk? Thromb Haemost 2006; 96: 14-18.
77. Lim W, Crowther M, Eikelboom J. Management of antiphospholipid antibody syndrome: A systematic review. JAMA 2006; 295: 1050-1057.
78. Larsen T, Johnsen S, Gislum M, Moller C, Larsen H, Sorensen H. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J Thromb Haemost 2005; 3: 300-304.
79. Nijkeuter M, Ginsberg J, Huisman M. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: A systematic review. J Thromb Haemost 2006; 4: 496-500.
80. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in health postmenopausal women. JAMA 2002; 288: 321-333.
81. Perez G, Rodriguez G, Castellsague J, Duque O. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ 1997; 314: 796-800.
82. Jick H, Derby L, Myers M, Vasilakis C, Newton K. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal estrogens. Lancet 1996; 348: 981-983.
83. Hoibraaten E, Abdelnoor M, Sandset P. Hormone replacement therapy with estradiol and risk of venous thromboembolism: A population-based case-control study. Thromb Haemost 1999; 82: 1218-1221.
84. Grodstein F, Stampfer M, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
85. Daly E, Vessey M, Hawkins M, Carson J, Gough P, Marsh S. Risk of venous thromboembolism in users or hormone replacement therapy. Lancet 1996; 348: 977-980.
86. Perez-Gutthann S, Rodgriguez L, Castellsague J, Oliart A. Hormone replacement therapy and risk of venous thromboembolism: Population-based case-control study. BMJ 1997; 314: 796-800.
87. Huller S, Furberg C, Barrett-Connor E, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
88. Kristensen S, Abrahamsen B, Madsen S, et al. Occurrence of venous thromboembolism is not increased in women taking postmenopausal hormone replacement therapy in the Danish Osteoporosis Prevention Study (DOPS). J Thromb Haemost 2005:3 (Suppl).
89. Douketis J. Hormone replacement therapy and risk for venous thromboembolism: What's new and how do these findings influence clinical practice? Curr Opin Hematol 2005; 12: 395-400.
90. Curb D, Prentice R, Bray P, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772-780.
91. Smith N, Heckbert S, Lemaitre R, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581-1587.
92. Smith N, Heckbert S, Doggen C, et al. The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. J Thromb Haemost 2006; 4: 1701-1706.
93. Straczek C, Oger E, de Jonage-Canonico B, et al. Prothrombotic mutations, hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation 2005; 112: 3495-3500.
94. Scarabin P, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacment therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
95. Canonico M, Oger E, Plu-Bureau G, et al. for the Estrogen and Thromboembolism Risk (ESTHER) Study. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007; 115: 840-845.
96. Rexrode K, Manson J. Are some types of hormone therapy safer than others?: Lessons from the estrogen and thromboembolism risk study. Circulation 2007; 115: 820-822.
97. Fitzpatrick LA. Selective estrogen receptor modulators and phytoestrogens: New therapies for the postmenopausal woman. Mayo Clin Proc 1999; 74: 601-607.
98. ACOG Task Force Report on Hormone Therapy. Frequently asked questions about hormone therapy. Washington, DC: The American College of Obstetricians and Gynecologists; October 2004.
99. Kujovich J. Hormones and pregnancy: Thromboembolic risks for women. Br J Haematol 2004; 126: 443-454.
100. Barrett-Connor E, Mosca L, Collings P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125-137.
101. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset P. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemost 2000; 84: 961-967.
102. Rosendaal F, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116:851-854.
103. Cushman M, Kuller L, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-1580.
104. Douketis J, Julian J. The effect of prothrombotic blood abnormalities on the association between hormone replacement therapy and venous thromboembolism. J Thromb Haemost 2003; 1 (suppl 1): OC394.
105. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: A meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80- 90.
106. Savelli S, Kerlin B, Springer M, Monda K, Thornton J, Blanchong C. Recommendations for screening for thrombophilic tendencies in teenage females prior to contraceptive initiation. J Pediatr Adolesc Gynecol 2006; 19: 313-316.
107. Gates S, Brocklehurst P, Davis L. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Cochrane review). Cochrane Database Syst Rev 2002; CD001689.
108. Brill-Edwards P, Ginsberg J, Gent M. et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343: 1439-1444.
109. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3: 949-954.
110. De Stefano V, Martinelli I, Rossi E. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135: 386-391.
111. Blickstein D. The Seventh American College of Chest Physicians Guidelines for Antenatal and Peripartum Management of Thrombophilia: A tutorial. Obstet Gynecol Clin North Am 2006; 33: 499-505.
112. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: The LIVE-ENOX study. J Thromb Haemost 2005; 3: 227-229.
113. Bates S, Greer I, Hirsh J, Ginsberg J. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 suppl: 627S-644S.
114. Greer I. Prevention of venous thromboembolism in pregnancy. Eur J Med Res 2004; 9: 134-145.
115. Wijesiriwardana A, Lees D, Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis 2006; 17: 147-149.
116. Casele H, Grobman W. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet Gynecol 2006; 108: 535-540.
117. Rajput V, Rana H. Incidence of pregnancy-associated venous thromboembolism [letter]. Ann Intern Med 2006; 144:453.
118. Greer I, Nelson-Percy C. Low-molecular-weight heparins for prophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. J Thromb Haemost 2005; 3 (Suppl).
119. Smith M, Norris L, Steer P, Savidge G, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190: 495-501.
120. Leonhardt G, Gaul C, Nietsch H, Buerke M, Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006; 21: 271-276.
121. Kawamata, K, Chiba Y, Tanaka R, Higashi, M, Nishigami K. Experience of temporary inferior vena cava filters inserted in the perinatal period to prevent pulmonary embolism in pregnant women with deep vein thrombosis. J Vasc Surg 2005; 41: 652-656.
122. Hurbaneck, J, Jaffer, A, Morra N, et al. Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty. Thromb Haemost 2004; 92: 337-343.
123. Douketis J, Julian J. Costantini, L for the HRT-DVT Study Group. HRT and the risk of DVT: The role or progesterone and other factors in the pathogenesis of HRT-associated DVT. Thromb Haemost 2001; 86 (suppl 1): OC850.